Association Between Expedited Review Designations and the US or Global Burden of Disease for Drugs Approved by the US Food and Drug Administration, 2010–2019: A Cross-sectional Analysis

Authors

Matthew J. Jackson
Gregory Vaughan
Fred D. Ledley

Document Type

Article

Publication Date

3-12-2024

Publication Title

BMJ Open

First Page

1

Last Page

12

DOI

doi:10.1136/ bmjopen-2023-076542

Abstract

Pharmaceutical innovation can contribute to reducing the burden of disease in human populations. This research asks whether products approved by the US Food and Drug Administration (FDA) from 2010 to 2019 and expedited review programmes incentivising development of products for serious disease were aligned with the US or global burden of disease.

Recommended Citation

Jackson, Matthew J.; Vaughan, Gregory; and Ledley, Fred D., 2024. Association Between Expedited Review Designations and the US or Global Burden of Disease for Drugs Approved by the US Food and Drug Administration, 2010–2019: A Cross-sectional Analysis, BMJ Open.